Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

ItalyBack to Italy

Clinical trials in Milan – page 193

2 423 clinical trials in Milan, Italy across 15 research sites. Every trial is listed in the EU Clinical Trials Register and updated daily.

ItalyOur site in ItalyStudi-Clinici.it(opens in a new tab)
Milan at a glance
2 423
clinical trials
  • Research sites15
Type of trial
Recruitment status
Quick filters

2 423 trials in Milan

Open in trial search

Pulmonary arterial hypertension

Not recruiting

Study on the Effects of MK-5475 for Adults with Pulmonary Arterial Hypertension

Investigational
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:3-(4-{(5S)-4-Amino-2-[6-Chloro-1-(3,3,4,4,4-Pentafluorobutyl)-1H-Indazol-3-Yl]-5-Methyl-6-Oxo6,7-Dihydro-5H-Pyrrolo[2,3-D]Pyrimidin-5-Yl}Phenyl)Propanoic Acid
  • Sponsor:Merck Sharp & Dohme LLC

Schizophrenia

Not recruiting

Study on Valbenazine for Patients with Schizophrenia Not Responding Well to Antipsychotic Treatment

Investigational
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Valbenazine Ditosylate
  • Sponsor:Neurocrine Biosciences Inc.

Neurotrophic keratopathy

Not recruiting

Study on the Safety and Effectiveness of RGN-259 Eye Drops for Patients with Neurotrophic Keratopathy

Investigational
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Timbetasin Acetate
  • Sponsor:Regentree LLC

Mantle cell lymphoma+2

Not recruiting

Study on KTE-X19 CAR-T Cell Therapy for Patients with Relapsed or Refractory Mantle Cell Lymphoma Responding Partially to Ibrutinib

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Fludarabine
  • Sponsor:Fondazione IRCCS Istituto Nazionale Dei Tumori

Study on Secukinumab and Prednisone for Patients with Polymyalgia Rheumatica Who Have Recently Relapsed

Not recruiting
Registered drug
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Prednisone
  • Sponsor:Novartis Pharma AG

Colorectal cancer metastatic

Not recruiting

Study of ZN-c3, Encorafenib, and Cetuximab for Adults with Metastatic Colorectal Cancer

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years
  • Substances:Azenosertib
  • Sponsor:K-Group Beta Inc.

Ovarian epithelial cancer stage IV+1

Not recruiting

Study on the Effectiveness of Olaparib and Bevacizumab for Maintenance Treatment in Patients with HRD-Positive Ovarian Cancer

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Bevacizumab
  • Sponsor:Istituto Di Ricerche Farmacologiche Mario Negri

Hepatocellular carcinoma

Not recruiting

Study of Pembrolizumab as Additional Treatment for Patients with Liver Cancer (Hepatocellular Carcinoma) After Surgery or Local Ablation

Registered drug
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Pembrolizumab
  • Sponsor:Merck Sharp & Dohme LLC

Dementia Alzheimer's type

Not recruiting

Study on the Safety and Effectiveness of MK-1942 for Patients with Mild to Moderate Alzheimer's Disease

Investigational
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:MK-1942
  • Sponsor:Merck Sharp & Dohme LLC

Haemophilia

Not recruiting

Study on Fitusiran for Preventing Bleeding in Males Aged 12 and Older with Severe Hemophilia A or B, with or without Inhibitors

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Fitusiran
  • Sponsor:Sanofi-Aventis Recherche & Developpement

Breast cancer+2

Not recruiting

Comparing inavolisib plus fulvestrant versus alpelisib plus fulvestrant in patients with advanced hormone receptor-positive, HER2-negative breast cancer with PIK3CA mutation

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Alpelisib
  • Sponsor:F. Hoffmann-La Roche AG

Focal segmental glomerulosclerosis

Not recruiting

Study on the Effectiveness and Safety of DMX-200 with Losartan in Adults with Focal Segmental Glomerulosclerosis

Registered drug
Countries:ItalyItaly
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Azilsartan Medoxomil
  • Sponsor:Dimerix Bioscience Pty Limited

Other cities in Italy

The busiest research cities in the country

All 237 cities in Italy

Clinical research in Milan

What the registry says about research in the country

01 Oncology Research

Innovative clinical trials focusing on colorectal cancer, breast cancer prevention, and advanced solid tumors. Studies include evaluation of novel therapeutic approaches and diagnostic methods.

  • Metastatic Colorectal Cancer Treatment
  • Breast Cancer Prevention Strategies
  • Advanced Solid Malignancies

Research emphasizes personalized treatment approaches and preventive interventions for high-risk patients.

02 Neurological Disorders

Research initiatives targeting neurodegenerative conditions and chronic headache disorders, with studies examining innovative therapeutic approaches.

  • Frontotemporal Dementia
  • Parkinson's Disease
  • Migraine Treatment

Focus on developing targeted therapies and understanding disease mechanisms.

03 Immunology and Infectious Diseases

Studies investigating treatments for autoimmune conditions and infectious diseases, including preventive approaches and therapeutic interventions.

  • Immune Thrombocytopenia
  • RSV Prevention
  • HIV Prevention

Emphasis on developing novel preventive strategies and therapeutic solutions.

Back to ItalyAll countries
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.